美國總統拜登就職致詞原文

 

January 20, 2021   Inaugural Address by President Joseph R. Biden, Jr. As Prepared for Delivery The United States Capitol Chief Justice Roberts, Vice President Harris, Speaker Pelosi, Leader Schumer, Leader McConnell, Vice President Pence, distinguished guests, and my fellow Americans.  This is America’s day. This is democracy’s day.  A day of history and hope. Of renewal and resolve. Through a crucible for the ages America has been tested anew and America has risen to the challenge.  Today, we celebrate the triumph not of a candidate, but of a cause, the cause of democracy. The will of the people has been heard and the will of the people has been heeded. We have learned again that democracy is precious. Democracy is fragile. And at this hour, my friends, democracy has prevailed. So now, on this hallowed ground where just days ago violence sought to shake this Capitol’s very foundation, we come together as one nation, under God, indivisible, to carry out the peaceful transfer of power as we have for more than two centuries.    We look ahead in our uniquely American way – restless, bold, optimistic – and set our sights on the nation we know we can be and we must be. I thank my predecessors of both parties for their presence here.  I thank them from the bottom of my heart.  You know the resilience of our Constitution and the strength of our nation.  As does President Carter, who I spoke to last night but who cannot be with us today, but whom we salute for his lifetime of service.  I have just taken the sacred oath each of these patriots took — an oath first sworn by George Washington.  But the American story depends not on any one of us, not on some of us, but on all of us. On “We the People” who seek a more perfect Union. This is a great nation and we are a good people.  Over the centuries through storm and strife, in peace and in war, we have come so far. But we still have far to go.  We will press forward with speed and urgency, for we have much to do in this winter of peril and possibility. Much to repair. Much to restore. Much to heal. Much to build. And much to gain.  Few periods in our nation’s history have been more challenging or difficult than the one we’re in now. A  once-in-a-century virus silently stalks the country.  It’s taken as many lives in one year as America lost in all of World War II. Millions of jobs have been lost. Hundreds of thousands of businesses closed. A cry for racial justice some 400 years in the making moves us. The dream of justice for all will be deferred no longer. A cry for survival comes from the planet itself. A cry that can’t be any more desperate or any more clear.  And now, a rise in political extremism, white supremacy, domestic terrorism that we must confront and we will defeat. To overcome these challenges – to restore the soul and to secure the future of America – requires more than words.  It requires that most elusive of things in a democracy:  Unity. Unity. In another January in Washington, on New Year’s Day 1863, Abraham Lincoln signed the Emancipation Proclamation.  When he put pen to paper, the President said, “If my name ever goes down into history it will be for this act and my whole soul is in it.” My whole soul is in it. Today, on this January day, my whole soul is in this:  Bringing America together.  Uniting our people.   And uniting our nation. I ask every American to join me in this cause. Uniting to fight the common foes we face:  Anger, resentment, hatred. Extremism, lawlessness, violence. Disease, joblessness, hopelessness. With unity we can do great things. Important things. We can right wrongs. We can put people to work in good jobs. We can teach our children in safe schools. We can overcome this deadly virus. We can reward work, rebuild the middle class, and make health care  secure for all. We can deliver racial justice. We can make America, once again, the leading force for good in the world. I know speaking of unity can sound to some like a foolish fantasy.    I know the forces that divide us are deep and they are real. But I also know they are not new.  Our history has been a constant struggle between the American ideal that we are all created equal and the harsh, ugly reality that racism, nativism, fear, and demonization have long torn us apart. The battle is perennial.  Victory is never assured. Through the Civil War, the Great Depression, World War, 9/11, through struggle, sacrifice, and setbacks, our “better angels” have always prevailed.  In each of these moments, enough of us came together to carry all of us forward. And, we can do so now.  History, faith, and reason show the way, the way of unity. We can see each other not as adversaries but as neighbors. We can treat each other with dignity and respect. We can join forces, stop the shouting, and lower the temperature. For without unity, there is no peace, only bitterness and fury. No progress, only exhausting outrage. No nation, only a state of chaos. This is our historic moment of crisis and challenge, and unity is the path forward.  And, we must meet this moment as the United States of America.  If we do that, I guarantee you, we will not fail. We have never, ever, ever failed in America when we have acted together. And so today, at this time and in this place, let us start afresh. All of us. Let us listen to one another. Hear one another.  See one another. Show respect to one another. Politics need not be a raging fire destroying everything in its path. Every disagreement doesn’t have to be a cause for total war. And, we must reject a culture in which facts themselves are manipulated and even manufactured.  My fellow Americans, we have to be different than this.  America has to be better than this.  And, I believe America is better than this. Just look around. Here we stand, in the shadow of a Capitol dome that was completed amid the Civil War, when the Union itself hung in the balance.  Yet we endured and we prevailed. Here we stand looking out to the great Mall where Dr. King spoke of his dream. Here we stand, where 108 years ago at another inaugural, thousands of protestors tried to block brave women from marching for the right to vote.  Today, we mark the swearing-in of the first woman in American history elected to national office – Vice President Kamala Harris. Don’t tell me things can’t change.  Here we stand across the Potomac from Arlington National Cemetery, where heroes who gave the last full measure of devotion rest in eternal peace.  And here we stand, just days after a riotous mob thought they could use violence to silence the will of the people, to stop the work of our democracy, and to drive us from this sacred ground.  That did not happen. It will never happen. Not today.  Not tomorrow.  Not ever.  To all those who supported our campaign I am humbled by the faith you have placed in us. To all those who did not support us, let me say this: Hear me out as we move forward. Take a measure of me and my heart.  And if you still disagree, so be it.  That’s democracy. That’s America. The right to dissent peaceably, within the guardrails of our Republic, is perhaps our nation’s greatest strength. Yet hear me clearly: Disagreement must not lead to disunion. And I pledge this to you: I will be a President for all Americans.  I will fight as hard for those who did not support me as for those who did. Many centuries ago, Saint Augustine, a saint of my church, wrote that a people was a multitude defined by the common objects of their love. What are the common objects we love that define us as Americans? I think I know. Opportunity. Security. Liberty.  Dignity. Respect. Honor. And, yes, the truth. Recent weeks and months have taught us a painful lesson. There is truth and there are lies. Lies told for power and for profit. And each of us has a duty and responsibility, as citizens, as Americans, and especially as leaders – leaders who have pledged to honor our Constitution and protect our nation — to defend the truth and to defeat the lies. I understand that many Americans view the future with some fear and trepidation.  I understand they worry about their jobs, about taking care of their families, about what comes next. I get it.  But the answer is not to turn inward, to retreat into competing factions, distrusting those who don’t look like you do, or worship the way you do, or don’t get their news from the same sources you do.  We must end this uncivil war that pits red against blue, rural versus urban, conservative versus liberal.  We can do this if we open our souls instead of hardening our hearts. If we show a little tolerance and humility. If we’re willing to stand in the other person’s shoes just for a moment. Because here is the thing about life: There is no accounting for what fate will deal you.  There are some days when we need a hand.  There are other days when we’re called on to lend one. That is how we must be with one another. And, if we are this way, our country will be stronger, more prosperous, more ready for the future.  My fellow Americans, in the work ahead of us, we will need each other.  We will need all our strength to persevere through this dark winter.  We are entering what may well be the toughest and deadliest period of the virus.  We must set aside the politics and finally face this pandemic as one nation.  I promise you this: as the Bible says weeping may endure for a night but joy cometh in the morning.  We will get through this, together The world is watching today.  So here is my message to those beyond our borders: America has been tested and we have come out stronger for it.  We will repair our alliances and engage with the world once again.  Not to meet yesterday’s challenges, but today’s and tomorrow’s.   We will lead not merely by the example of our power but by the power of our example. We will be a strong and trusted partner for peace, progress, and security. We have been through so much in this nation. And, in my first act as President, I would like to ask you to join me in a moment of silent prayer to remember all those we lost this past year to the pandemic.  To those 400,000 fellow Americans – mothers and fathers, husbands and wives, sons and daughters, friends, neighbors, and co-workers.  We will honor them by becoming the people and nation we know we can and should be.  Let us say a silent prayer for those who lost their lives, for those they left behind, and for our country.  Amen.  This is a time of testing.  We face an attack on democracy and on truth. A raging virus. Growing inequity. The sting of systemic racism. A climate in crisis. America’s role in the world. Any one of these would be enough to challenge us in profound ways. But the fact is we face them all at once, presenting this nation with the gravest of responsibilities.  Now we must step up.  All of us.  It is a time for boldness, for there is so much to do. And, this is certain.  We will be judged, you and I, for how we resolve the cascading crises of our era.  Will we rise to the occasion?  Will we master this rare and difficult hour?  Will we meet our obligations and pass along a new and better world for our children? I believe we must and I believe we will.  And when we do, we will write the next chapter in the American story.  It’s a story that might sound something like a song that means a lot to me.  It’s called “American Anthem” and there is one verse stands out for me:  “The work and prayers of centuries have brought us to this day What shall be our legacy? What will our children say?... Let me know in my heart When my days are through America America I gave my best to you.” Let us add our own work and prayers to the unfolding story of our nation. If we do this then when our days are through our children and our children’s children will say of us they gave their best.  They did their duty. They healed a broken land. My fellow Americans, I close today where I began, with a sacred oath. Before God and all of you I give you my word. I will always level with you. I will defend the Constitution. I will defend our democracy. I will defend America. I will give my all in your service thinking not of power, but of possibilities. Not of personal interest, but of the public good.  And together, we shall write an American story of hope, not fear. Of unity, not division. Of light, not darkness. An American story of decency and dignity. Of love and of healing.  Of greatness and of goodness. May this be the story that guides us. The story that inspires us. The story that tells ages yet to come that we answered the call of history. We met the moment. That democracy and hope, truth and justice, did not die on our watch but thrived. That our America secured liberty at home and stood once again as a beacon to the world. That is what we owe our forebearers, one another, and generations to follow. So, with purpose and resolve we turn to the tasks of our time.  Sustained by faith.  Driven by conviction. And, devoted to one another and to this country we love with all our hearts. May God bless America and may God protect our troops. Thank you, America.

陳秀惠推廣尼雅舞 要帶你跳出一段不同的人生

學生在陳秀惠練尼雅舞時捉住了一個老師的鏡頭。
(陳秀惠提供)

         (Boston Orange)簡單，優雅的動，就能讓人身體健康，思想清晰，情感舒暢，精神愉快? 大波士頓地區第一位台裔尼雅健身舞蹈(Nia Fitness)老師陳秀惠指出，"尼雅”還能幫助帕金森症患者改善症狀，她希望在大波士頓，甚至台灣推廣這舞蹈、運動。

 陳秀惠在大波士頓猶太社區中心擔任帕金森症舞蹈課老師，親眼看到帕金森症患者跳尼雅舞時，神情那麼快樂，心中非常感動。後來知道跳尼雅舞能幫助人在音樂中整合神經肌肉，於是希望更努力的讓更多人認識這看似簡單，卻對人們身心健康都有極大好處的”舞蹈”。 

從台灣來，目前住在波士頓郊區的陳秀惠，6歲就開始學芭蕾舞，上大學時期通過台灣教育部甄選加入青訪團，要到美國各個大學巡演，宣揚中華音樂舞蹈，因而在教育部安排下曾經跟隨雲門舞集林懷民學舞，開始接觸並喜歡上民族現代舞。只是後來移居美國，相夫教子，她的一身舞藝也就放下了。

陳秀惠在戶外排練尼雅舞。(陳秀惠提供)

2000年時，她走進Needham成人教育中心，首次接觸到尼雅舞，所有關於舞蹈的記憶，小時候母親接送她學舞的感情，一下子泉湧而出，也開始迷上尼雅舞。

到牛頓市的波士頓運動俱樂部繼續學的時候，教她的老師鼓勵她去拿尼雅教師證，做代課幫手，沒想到她就從此不斷晉階，到奧勒岡州(OR)波特蘭(Portland)尼雅總部受訓數次之餘，還從創辦人Debbie Rosas那兒學到更深層，融合東西方瑜珈，武術及禪修精神的尼雅舞內涵，也拿到了黑帶一級教師資格，成為尼雅舞在全世界49國的2500名尼雅舞教師之一。

 最近這幾年，陳秀惠每次回台灣，都積極推廣尼雅舞蹈操。她的青訪團好友，前衛生署副署長宋晏仁醫師還出了本書，「終身瘦用- 211全平衡瘦身法」，提及尼雅舞好處。在大波士頓，她也為慈濟功德會波士頓聯絡處，波士頓北一女校友會舉辦過免費課程。她還開了尼雅公益課 ，一邊提倡舞動健身，一邊回饋社區，為Needham鎮上的備餐間(food pantry)，耆英項目募款。 (僑務電子報授權轉載)

陳秀惠在疫情期間透過網路交尼雅舞。(周菊子攝)

波士頓教師工會支援殘障兒童論壇 1/26

波士頓教師工會(BTU)將於1月26日(週二)下午7點至8點半，在網上舉辦"支持殘障兒童(Supporting Students with Disabilities)”論壇，討論如何在家庭和教師間建立合作關係，在病毒大流行期間幫助殘障兒童。活動將有中文翻譯，報名網址為http:Familyforum。

會場將有中文翻譯

波士頓洪門致公堂首名女主席余麗媖連任第三年

 

波士頓洪門致公堂連任主席余麗媖(前右二)，湯偉立(前左三)，和前右起，阮偉昌，阮振牆，伍伯和，黃國威，
梅少華等人出席2021就職典禮。(波士頓洪門致公堂提供)

       (Boston) 波士頓洪門致公堂因為新冠病毒(COVID-19)疫情，未辦理改選，所有職員2021連任一年，使得波士頓洪門才剛於2019締造歷史，選出有史以來首名女主席余麗媖，今年又打破紀錄，讓這名女主席連任第3年。

   

洪門致公堂元老伍伯和(又二)，監堂阮振強(左二)監交印信，主席
余麗媖(右一)，湯偉立(左一)接受印信。(波士頓洪門致公堂提供)

         在疫情期間，所有社團活動都已減至最低程度，但為表示對洪門出任職員者的重視，波士頓洪門致公堂元老伍伯和，監堂阮振強等人，日前仍召集堂內主要幹部，但未邀外賓地舉行了簡單隆重的就職典禮。

             余麗媖指出，波士頓洪門致公堂作為社區內的龍頭組織之一，每年都捐款支持Boston Shriners Hospital，波士頓亞裔青年會(YES)，中華廣教學校等組織。去年紐英崙中華公所，波士頓華商會買口罩，捐贈給地方醫護機構及人員，該堂也義不容辭的捐款支持。所有這些服務僑社的活動，今年也都將繼續。

右起，伍伯和，湯偉立，阮振強，余麗媖等人切金豬，敬告關公。
(波士頓洪門致公堂提供)

           洪門致公堂是美國歷史最悠久的華人社團之一，創立於1848年，在1911年黃花崗起義失敗，同盟會向海外求援時，曾合共捐助7萬美元，和中華民國可謂關係密切。

1904年孫中山到波士頓為反清革命募款時，在波士頓創立安良工商會的洪門大老司徒美堂不但親自接待，還為孫中山當了5個月保鏢兼廚師，曾安排孫中山在波士頓泰勒街上的洪門致公堂會所內住過。Youtube上藉「粵講粵有理」的一輯「正本清源」視頻，澄清該堂和尹國駒所創辦的「世界洪門歷史文

家中一門四代都有洪門人的余麗媖指出，波士頓洪門致公堂和中華民國，也因此有著傳統淵源。她也補充說明，洪門沿襲歷史的組織架構，規矩很多，十分嚴明，不是任何人都可以加入洪門，或自稱洪門人的。

2020年底，舊金山洪門致公堂在化協會」沒有關係。

余麗媖表示，波士頓地區也有人在傳閱這視頻，主要也是為了澄清互無關係，說明洪門立場。

波士頓洪門致公堂的2021年主要幹部包括主席余麗媖、湯偉立，秘書陳國漢，財政林文健，外交張國威，理財阮偉昌，核數葉偉綱，康樂黎益置，幹事鄧安，洪清會長陳偉倫。

波士頓安良工商會會長伍輝民表示，由於疫情，該會今年也未辦理幹部改選，原班人馬連任，依序為會長陳文棟，伍輝民，幫辦黃國健，李天生，鄧北海，司徒炳思，書記方永康，財政陳文浩，外交阮鴻燦，黃立輝，庶務劉樹榮。(僑務電子報授權)

美國新冠病毒死亡人數打破40萬大關

 

麻州政府擴大疫苗施打 芬衛球場外 陸續增40家藥店做疫苗站

麻州州長查理貝克(Charlie Baker)。檔案照片。

          (Boston Orange 編譯)麻州政府今日宣佈，將把新冠病毒疫苗站擴大到麻州每個社區的藥店，醫療服務提供者，以及第2個大型疫苗注射站去，以期疫苗施打的速度可每週以千計的增加。

              查詢麻州疫苗推出的基本標準，可上網https://www.mass.gov/info-details/covid-19-vaccine-locations-for-individuals-currently-eligible-to-be-vaccinated。

              麻州政府表示，麻州藉著和全州各地的CVS Health及華格林(Walgreens)藥店合作，是全美各州首先推出聯邦疾病防治中心新冠病毒藥店合作-第一期的其中一州。本週開始將每週發送總額1萬劑的疫苗到至少15家CVS和華格林藥店去，供符合第一優先階段的民眾接種。

麻州疫苗注射時間表。

             

                          第一批的這15家藥店，分佈在Greenfield，秋河市(Fall River)，塞冷市(Salem)，南亞茅斯(South Yarmouth)，匹茲菲爾德(Pittsfield)，李市(Lee)，荷頓(Holden)，嘉納(Gardner)，海牙尼斯(Hyannis)，馬什皮(Mashpee)，梭莫塞(Somerset)，費爾海文(Fairhaven)，哈佛喜爾(Haverhill)，索格斯(Saugus)及丹佛斯(Danvers)等市鎮。

              符合第一階段資格者，即日起就可到前述地點的疫苗站接種疫苗。查詢可上網https://www.mass.gov/info-details/covid-19-vaccine-locations-for-individuals-currently-eligible-to-be-vaccinated。

              1月25日起再增加40個施打疫苗站。合作夥伴將包括Wegmans，Big Y，Price Chopper，Stop & Shop，以及Hannaford等這些超市或商店。

              麻州政府還宣佈芬衛球場(Fenway Park)將繼吉列體育館(Gillette Stadium)之後，成為麻州的第2個大規模疫苗站。芬衛球場將從2月1日起開始，每天為符合第一階段資格的500人施打疫苗，然後逐步增加到每日1000人。聯邦疾病防治中心醫療人員將和貝斯以色列女執事醫療中心(Beth Israel Deaconess Medical Center)合作，為民眾施打疫苗。這個疫苗站估計會一直開到四月中。麻州政府也在和波士頓市府商量，在波士頓找個地方做長期的疫苗注射站。

              吉列體育館已從今日開始每日為1000人注射疫苗，目標是每日5000人。指揮中心正在確認另外幾個大型疫苗注射站。

              麻州政府也宣佈，之前為第一線工作人員施打疫苗的麻州大學安赫斯特分校(Amherst)，將擴大疫苗注射服務，以便也能立即為符合第一階段資格的民眾施打疫苗。這個地點主要是為麻州西部民眾服務。這個疫苗站的預約網址為https://www.umass.edu/coronavirus/vaccine。

              指揮中心正在和麻州醫療協會(Massachusetts Medical Society (MMS) )，以及麻州布瑞根總醫院(Mass General Brigham (MGB))合作，監管這一項目。在此計畫下，麻州每個地區的醫院都是一個疫苗站。

              參加這計畫的醫院包括麻州布瑞根總醫院，羅倫斯總醫院，Signature Brockton Hospital，麻州大學紀念醫療中心(UMass Memorial Medical Center)，灣州醫療中心(Baystate Medical Center)，以及伯克夏爾醫療中心(Berkshire Medical Center)。

              為加速符合第一階段資格民眾接種疫苗速度，麻州政府推出醫院站點計畫(Hospital Depot Initiative)。這計畫將容許獨立作業的醫生，取得疫苗，照第一階段優先準則，為民眾施打疫苗。

              目前在第一階段下符合施打疫苗資格者，包括直接面對照顧新冠病毒患者的診所及非門診醫護工作人員，長照機構，頤養院及輔助居住場所，第一線工作人員(急救員，消防員，警察等)，還有集體護理場所(包括監獄及庇護所)。

Baker-Polito Administration Launches COVID-19 Vaccine CDC Pharmacy Partnership - Phase 1, Expands Vaccine Locations & Names Fenway Park as Mass Vaccination Site

Command Center Announces New Vaccine Sites to Administer Several Thousands More Shots Per Week Statewide

 

BOSTON — Today, the Baker-Polito Administration announced the expansion of more vaccine locations in each region of the Commonwealth at pharmacies, health care providers and a second mass vaccination site to boost the capacity to administer vaccines per week by the thousands. The Commonwealth will continue to add more vaccination sites throughout Massachusetts. Information on available sites will be available on a rolling basis here. 

 

First, the Administration announced that Massachusetts will become one of the first states in the nation to launch the COVID-19 CDC Pharmacy Partnership - Phase 1 with CVS Health and Walgreens pharmacies located throughout the Commonwealth. Starting this week, this program will deliver a total of 10,000 doses to at least 15 CVS Health and Walgreens pharmacies a week for eligible residents in the Phase One priority groups.  

 

Second, the Administration announced that Fenway Park will become the state’s second mass vaccination site, joining Gillette Stadium. The ballpark will open on February 1^st to start administering up to 500 vaccines per day to eligible residents in the Phase One priority groups.

 

Next, the Administration also announced that UMass Amherst will expand their vaccination site to provide inoculations for eligible residents in Phase One priority groups. UMass Amherst has been providing vaccines to first responders, and plans to now offer vaccines to all eligible residents in Phase One priority groups immediately. 

 

Finally, to increase vaccine access for Phase 1 eligible priority groups, the Baker-Polito Administration is launching the Hospital Depot Initiative. This new program will facilitate access to COVID-19 vaccine for independent physician practices prioritized under Phase 1. 

Current eligible groups under Phase 1 include: Clinical and non-clinical health care workers doing direct and COVID-facing care; Long term care facilities, rest homes and assisted living facilities; First responders (EMS, Fire, Police); and Congregate care settings (including corrections and shelters).

 

CDC Pharmacy Partnership - Phase 1

 

Massachusetts will be among the first states to activate retail pharmacy vaccination at scale through select CVS Health and Walgreens, which will start inoculating eligible residents in Phase One priority groups by appointment.

 

Starting this week, at least 15 CVS Health and Walgreens, located in areas of the state where there is currently less access to convenient vaccine sites, will receive a total of 10,000 vaccines to administer this week. The first 15 locations are located in Greenfield, Fall River, Salem, South Yarmouth, Pittsfield, Lee, Holden, Gardner, Hyannis, Mashpee, Somerset, Fairhaven, Haverhill, Saugus and Danvers. Eligible residents in Phase One priority groups can view sites and book an appointment today by clicking here.

 

Approximately 40 vaccination sites will be added the week of 1/25 through current partners and collaboration with additional partners (Wegmans, Big Y, Price Chopper, Stop & Shop, Hannaford). Massachusetts expects to increase vaccine volume through retail pharmacies in the coming weeks. The Command Center will provide more details as pharmacy partners and sites come online.

 

Fenway Park Named as Second Mass Vaccination Site

 

Fenway Park will be the state’s second mass vaccination site and will open on February 1^st.  Initially, the ballpark is scheduled to administer 500 vaccines per day by appointment and will ramp up to providing 1,000 vaccines per day soon to eligible residents in Phase One priority groups. CIC Health will operate the site, with Beth Israel Deaconess Medical Center, part of Beth Israel Lahey Health, as the medical director.

 

The site is expected to stay open through the beginning of baseball season in early April. The Command Center is also working with the City of Boston to identify and set up a longer-term vaccine site in Boston.

 

Last week, the Administration announced Gillette Stadium as the first mass vaccination site, which opened for eligible Phase One groups yesterday. This week, the site is expected to work up to administering over 1,000 vaccinations per day, and soon after, 5,000 vaccinations per day. Eligible residents in Phase 1 priority groups can book an appointment at Gillette Stadium by clicking here.

 

The Command Center is finalizing plans for several other mass vaccination sites.

UMass Vaccination Site Expansion

 

Beginning today, the University of Massachusetts at Amherst has expanded their role to administer COVID-19 vaccines, providing vaccinations for all eligible groups in Phase One of the state’s distribution plan. This high capacity site will serve eligible groups in the Western Mass area.

 

Appointments for the UMass Amherst vaccination site can be booked here.

 

Hospital Depot Initiative

 

To increase vaccine access for residents in eligible Phase 1 priority groups, the Baker-Polito Administration is launching the Hospital Depot Initiative.

 

This new program will facilitate access to COVID-19 vaccines for independent COVID-facing physician practices prioritized under Phase 1. The Massachusetts COVID-19 Command Center and DPH, in collaboration with the Massachusetts Medical Society (MMS) and Mass General Brigham (MGB), is managing this initiative starting with COVID-facing health care workers.

 

Under this initiative, hospitals serving each region of the state have been identified as a depot to assist the Commonwealth with its vaccination distribution efforts. For clinical practices that are unable, due to their staff size and storage capacity, to receive larger, direct allocations of vaccine, a depot hospital will receive doses on their behalf and redistribute vaccine and all ancillary materials for office-based vaccination. In some cases, the hospital will provide direct vaccination to health care workers. The Massachusetts Medical Society is managing communications and coordination with physician practices.

 

Participating hospitals include:

 

Mass General Brigham, Lawrence General Hospital, Signature Brockton Hospital, UMass Memorial Medical Center, Baystate Medical Center and Berkshire Medical Center. To learn more about this program, click here.

紐英崙美中藥協第22屆年會 1/23

The 22nd SAPA-NE Annual Conference

A New Era in Biotech and Life Science

 

Sat, Jan 23 | Free Zoom Webinar

9:00 AM – 6:00 PM EST

Seats are limited

Please register ASAP

Register Now (Free)

Time: Sat, Jan 23rd, 9:00 AM – 6:00 PM EST

Language: English

Venue: Zoom Webinar, Spatial Chat (Virtual Networking, Job Hunting, Vendor Show)

Speakers & Presentation Topics

Register Now (Free)

Agenda

Morning Sessions: 9:00AM-12:30PM

Noon Sessions: 12:30PM-2:00PM

Afternoon Sessions: 2:00PM-6:00PM

Register Now (Free)

Speaker Bio

Dan Barouch, M.D., Ph.D.

Member, National Academy of Medicine; William Bosworth Castle Professor of Medicine, Harvard Medical School; Director, Center for Virology and Vaccine Research, BIDMC; Member, Ragon Institute of MGH, MIT, and Harvard

Eric Fischer, Ph.D. 

Eric Fischeris an Independent Investigator at Dana-Farber Cancer Institute, Associate Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and Co-Director of the DFCI Center for Protein Degradation. He and his lab have significantly contributed to our understanding of small molecule mediated protein degradation, and its widespread application in academia and industry. Dr. Fischer has co-founded Civetta Therapeutics, Jengu Therapeutics, and Neomorph and serves on the scientific advisory board for the Institute for Protein Innovation.

John Evans, MBA

John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans is also a Venture Partner with ARCH Venture Partners.

Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice) and MedImmune.

Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.

Jamie Stokes, Ph.D.

Jamie received his PhD from University of Cambridge in 2014. Between 2014 and 2017 Jamie was a Roche Postdoctoral Research Fellow at Cambridge where he worked on a number of projects at the chemistry-biology interface including the design and synthesis of de-novo antibiotic-quorum sensing small molecule conjugates and the development of methodology to allow access to diverse collections of small molecule screening collections. Jamie has worked at Concept Life Sciences since 2017 on a number of different medicinal chemistry programs and has a special interest in new approaches to synthesis and antibody drug conjugates.

Zonghai Li, M.D., Ph.D.

Zonghai Li is the Chairman, Chief Executive Officer, Chief Scientific Officer and Founder of CARsgen Therapeutics. He is dedicated himself to develop curable treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become one of the most widely used peptides in antitumor study now. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper and advancing the first clinical trial of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. He earned a M.D. and M.S. from Xiangya Medical School of Central South University and a Ph.D. from Fudan University.

Liang Schweizer, Ph.D.

Liang Schweizer is the co-founder, President and CEO of HiFiBiO Therapeutics, an emerging multinational biotherapeutics company. Previously, she was a co-founder and CSO for Harbour Biomed. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi and Director of Leads Evaluation at Bristol-Myers Squibb Company. Under her leadership, her various teams made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple immunomodulation drug candidates.

Dian Su, Ph.D.

Dian is a Senior Scientist in Drug Metabolism and Pharmacokinetics (DMPK) at Genentech. Her research focus has been on ADC/small molecule/peptide DMPK areas mainly in the pre-clinical stage. At DMPK, her primary focus lies in small molecule and peptide drug metabolism in discovery stage. In this role, her responsibilities include: 1) developing new generation assays for metabolite identification (Met ID) to improve the throughput and tackle challenges associated with drug metabolite ID; 2) exploring deep understanding of metabolite formation and biological impact, and establish structure−metabolism relationship (SMR) for drug metabolites. 

Yan Chen, Ph.D. Founder, President and CEO of Elpis Biopharmaceuticals

Yan brings more than 20 years of expertise in both mRNA display technology and biologic drug discovery in the oncology disease area. She was Biotherapeutics Discovery Head at Juno Therapeutics in Boston and Senior Vice President of Research at X-Body Biosciences which was acquired by Juno in 2015. Previously, she was an investigator and project leader in Oncology Biotherapeutics at Novartis Institutes for Biomedical Research. Earlier in her career, she was a scientist at Phylos and Adnexus playing instrumental roles in establishing the mRNA antibody and protein display technology platforms. Yan was a postdoctoral trainee in Immunology at Tufts Medical School and received her PhD in Tumor Immunology from National University of Singapore. She is the co-inventor of more than 20 antibody technologies and biologic therapeutics patents.

Sanchayita Ghose, Ph.D.

Sanchayita Ghose is currently the Executive Director of Global Downstream Bioprocess Development at Bristol Myers Squibb.  She leads a multi-site team responsible for downstream process development of BMS’ entire clinical biologics portfolio. Sanchayita has > 20 years of experience in bioprocess development with increasing roles of responsibility in a variety of biopharmaceutical companies: BMS (9), Amgen (6), Biogen (5). Over her career, she has made numerous technical contributions in this field and is the author of > 100 conference presentations, publications, book chapters and patents. She has a PhD in Chemical & Biological Engineering from Prof. Steve Cramer’s lab at Rensselaer (Troy, NY) and a BS in Chemical Engineering from Jadavpur University, India. Sanchayita is the mom of two-school aged kids and has lived if four US states across both coasts. In her free time, she enjoys travel, reading and hiking.

Brad Warsen

Brad Warsen is the Executive Director of Quality for the Devens Cell Therapy Facility at Bristol Myers Squibb.  Brad joined Bristol Myers Squibb in 2013 and previously served as the Head of Quality for US Biologics overseeing quality operations at the Devens and Syracuse sites.  Previous to this, he served as the Director of Quality at Devens, interim Director of Quality at Syracuse and as head of Quality Control Operations and Quality Assurance Operations both at Devens.  Brad has over 20 years of quality experience and previously served in quality leadership roles overseeing external manufacturing of biologics drug product at Shire and internal manufacturing of drug substance at Pfizer (including raw materials, compliance and QA Operations roles).  Brad began his career in manufacturing and process development at Pharm-Eco Laboratories and has a BS in Chemistry from Wheaton (IL) College.

Ji Li, Ph.D.

Ji Li is a Principal Scientist at BMS Kendall square site, Mechanism of Cancer Resistance TRC. He currently services as the Biology Lead for two drug discovery projects. He also leads a DepMap data analysis effort and leverages a genome-wide CRISPR screening platform to discover novel cancer targets. Prior to BMS, he worked at the Broad Institute and Dana-Farber Cancer Institute, where he led efforts in functional cancer genomics and the identification of synthetic lethality in breast cancer. Ji received his Ph.D in Cell Biology from NYU School of Medicine and a Bachelors’ degree in Biomedical Sciences from Peking University.

Chun Shao, Ph.D.

Chun Shao is a Principal Scientist at BMS Devens site, who joined Bristol-Myers Squibb in 2018. Chun interfaces closely with biologics process development upstream/downstream team and provides mass spec analytical support for bioprocess optimization. Chun is also co-leading Devens PAN chapter to drive Diversity & Inclusion initiatives. Prior to BMS, Chun worked at GlaxoSmithKline between 2016 and 2018 as characterization lead to support biologics process development. Chun received her PhD degree in Biochemistry from Boston University in 2016.  Chun is a big fan of Boston Celtics and Bruins and looking forward to shouting out loudly in TD garden soon with crowds!

Robert Flaumenhaft, M.D., Ph.D.

Dr. Flaumenhaft is a Professor of Medicine at Harvard Medical School and Chief of the Division of Hemostasis and Thrombosis. His laboratory focuses on endothelial & platelet biology and mechanisms of thrombus formation. Dr. Flaumenhaft is director of the T32 training program, “Blood Coagulation and Vascular Biology” and has editorial positions at Blood, JCI Insight, Thrombosis and Haemostasis, Thrombosis Research, and Seminars in Thrombosis and Hemostasis. He is Chairperson of the Hemostasis, Thrombosis, Blood Cells, and Transfusion NIH Study. He was the scientific co-chair of the ASH 2019 meeting and was the Chairman of the FASEB meeting on Functional Disulfide Bonds in Health and Disease. He has received awards from the Burroughs Wellcome Fund, the American Society of Hematology, and the American Heart Association. He was elected to the American Society for Clinical Investigation and subsequently to the American Association of Physicians. He is the recipient of an Outstanding Investigator Award from NIH.

Ai-Min Hui, MD, Ph.D. President of Global R&D, CMO, and Chair of the Scientific Committee of Fosun Pharma；Director of Shanghai Key Laboratory of Stem Cell Therapy; Former global Vice-President of Clinical Development Oncology at Sanofi

   Dr. Hui has 30 years of experiences in cancer treatment and innovative drug development in world's top medical centers and pharmaceutical companies. He has led the global development and registration of multiple small molecule and biologic anti-cancer drugs including Ixazomib, Isatuximab (anti-CD38) et al. He has recently led the deal of the joint development of an mRNA vaccine against COVID-19 BNT162 between BioNTech and Fosun Pharma and the execution of the program.

Julia Ding, Ph.D.

Julia Ding is leading process analytical development at Bristol Myers Squibb biologic development sites in US. She is leading diverse and cross-functional teams responsible for: Establishing strategic vision and implementation of global biologic PAT and rapid analysis technology development; Establishing and advancing new technologies in PAT and real-time release of biologic process; Developing and implementing analytical methodologies to enable and support bioprocess development and characterization; Advancing analytical CMC control strategies throughout biologic clinical development phases.

Prior to joining Bristol Myers Squibb, Julia Ding led a multifunctional analytical development team responsible for analytical assay development/validation/life cycle management, characterization and cGMP quality control testing of biologic products at PPD. Julia obtained her Ph.D. in physical organic chemistry from Emory University and postdoc from University of California at Berkeley.

Qingcong Lin, Ph.D.

Dr. Qingcong Lin is SVP of Biocytogen and CEO of Biocytogen Boston Corporation, focusing on providing services on gene-targeting and humanized mouse models, using cutting-edge ESC and CRISPR-Cas9 technology for immuno-oncology antibody candidate in vivo efficacy and toxicity assessment. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen Pharma Group. Dr. Lin has extensive expertise in multiple therapeutic areas, including cancer, CVMD, neurology, immunology & inflammation and various technologies, including genetically engineered mouse models, therapeutic antibody engineering, affinity maturation and optimization. Prior to joining Sheongen, Dr. Lin worked at Pfizer as a principal research scientist II and group leader of antibody engineering group. Before joining Pfizer, he worked at Wyeth and Harvard Medical School as Director of Gene Modification Lab of Harvard-Partners Center for Genetics and Genomics. Dr. Lin received Ph.D. from Albert-Einstein College of Medicine and completed his postdoctoral training at Harvard Medical School.

Ambar Boodhoo
Ambar is Americas Life Sciences Strategy and Transactions Leader at EY. He advises life sciences and health care clients on their capital and transaction agendas from strategy through execution, primarily focusing on large, complex investments. Over the last 20 years, he has supported private equity funds and corporate clients in transformational transactions to realize their strategic objectives and improve growth. His experience includes financial and operational diligence in taking companies private, leveraged recapitalizations, carve-outs, rollups, divestitures, PIPE and public financing. He has worked extensively in the UK and the US, and has led global engagements with clients and transaction teams in Europe, India, the Middle East and Asia.

Alex Li, Ph.D. Managing Director of TF Capital

Board Director of SAPA, previous president of SAPA-NE

Dr. Alex Li is a venture capital investor with investing experience in both United States and China. He specialized in the life science industry with focus on cutting edge technology and first-in-class therapeutic medicine. He currently serves on the boards of five innovated companies. TF Capital, one of the premium venture capital fund in China, have invested in near 100 companies, with successful exits like Zai Lab, Hua Medicine, Henlix, and Frontage, etc. Alex is one of the three investment decision committee members in TF Capital. Before Joining TF Capital, Alex was Managing Director of Fosun Pharma for three years. Alex worked as a research scientist in Biogen for seventeen years. Alex obtained his Ph.D. degree in Biochemistry, Cellular and Molecular Biology (BCMB) from the University of Tennessee.

Register Now (Free)

How to become a SAPA-NE Member?

Join/Renew SAPA-NE Membership

Paid Membership Rate

Student & Postdoc (Annual): $15

Professionals (Annual): $30

Life-time: $300

Note: Paid membership will be effective immediately after purchase.

2021 SAPA-NE年会将于1月23日线上举行——生物技术与生命科学的新纪元

美中药协SAPA Yesterday

挥别过往一年的惆怅，翘望来临在即的曙光，银装素裹的波士顿，少了昔日喧嚣鼎沸的熙熙攘攘，多了当下潜心探索的孜孜不倦。新英格兰美中医药开发协会（SAPA-NE）第22届年会将于2021年1月23日闪亮召开。PROTAC火了吗？COVID-19那一揽子事儿：vaccine？antibody？inhibitor？ADC再创辉煌？CAR-T能治实体瘤？来自著名学府、药企、新创公司的学术精英、企业领袖、投资英才、职场导师们与您相约Zoom，探讨PROTAC、Coronavirus、ADC、Gene/Cell therapy, 畅谈Career Development；与您相遇Spatialchat，令千里之遥的你我得以相逢畅谈于virtual party。本年会诣在助力您提升专业，拓展人脉，成就自我。SAPA-NE期待与各路同仁合力探寻医药发展之道，携手共创人类的美好未来。报名链接：http://sapa-neweb.org/ac2020 ，会议免费，位置有限，请尽快报名。本次会议将会设置独立SpatialChat会议室，欢迎各位会员企业报名参加Vendor Show，Vendor Show报名邮箱：info@sapa-neweb.org

As we say a somber goodbye to 2020, Boston, clad in silvery frost, is filled with a calm yet endless wonder at the dawn of a new year. The 22nd Annual Conference of Sino-American Pharmaceutical Professionals Association - New England/Boston (SAPA-NE) will be held on January 23, 2021. Is the emerging PROTAC gaining momentum? Everything about Coronavirus-19: vaccine, antibody, and inhibitor. Can ADC to be glory again? Can CAR-T treat solid tumors? Academic elites, business leaders, investment talents and career mentors from famous universities, pharmaceutical companies and start-up companies will meet with you at Zoom. Let's discuss PROTAC, Coronavirus, ADC, Gene / Cell therapy, and talk about Career Development. Despite the distance between us, you and I can meet at the virtual party on Spatialchat. This year's conference will help you to improve your professional skills, expand your network, and achieve success. SAPA-NE looks forward to working with colleagues to explore medicine development and create a better future for the mankind. Registration link: http://sapa-neweb.org/ac2020 . The conference is free but the spots are limited.  Please register as soon as possible. Independent Spatial Chat meeting room will be set up for this conference. Welcome to join Vendor Show. Email: info@sapa-neweb.org  

本次会议设置独立的Spatial Chat会议室，一直支持SAPA-NE的sponsor们也会在各个会议室进行Vendor Show。欢迎大家在会议期间或会议后互相交流讨论。

SAPA-NE期待与各路同仁合力探寻医药发展之道，携手共创人类的美好未来。线下相聚不易，借此机会，欢迎新老朋友线上相聚SAPA-NE年会，我们1月23日不见不散哦！

报名链接：http://sapa-neweb.org/ac2020 ，点击原文查看，会议免费，位置有限，请尽快报名。